Relevant bibliographies by topics / Lymph node;breast cancer;detection

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Lymph node;breast cancer;detection'

Author: Grafiati
Published: 4 June 2021
Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lymph node;breast cancer;detection.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lymph node;breast cancer;detection"

1

Nikitenko, R., V. Kosovan, K. Vorotyntseva, and E. Koichev. "The role of sentinel lymph nodes in breast cancer." Journal of Education, Health and Sport 12, no. 6 (June 30, 2022): 365–76. http://dx.doi.org/10.12775/jehs.2022.12.06.037.

Full text
Abstract:
Introduction. The problem of improving early diagnosis and prognosis of breast cancer remains one of the most actual for current oncological practice. Taking into account a close correlation between the general prevalence of breast neoplasms and mortality from breast cancer, this problem is not only of professional interest, but also has medical-social and socio-economic significance. The purpose of the study is to improve the quality of the sentinel lymph node detection in patients with breast cancer using ICG. Material and methods. At the period 2009–2016, 400 patients with T1-T3N0M0 breast cancer were operated on. All the patients were divided into two groups using two dyes – Patent Blue and ICG. The patients after mastectomy with a sentinel lymph node biopsy had a clinical diagnosis of T2-T3N0M0 breast cancer more often. In group I, 100 patients had the sentinel lymph node biopsy. Lymph node staining was performed using Patent Blue dye. In group II, sentinel lymph nodes biopsy was conducted with the Patent Blue dye and another fluorescent dye — ICG, which was also injected on the affected side of the breast. After ICG dye introduction, in 15 minutes the stained green lymph nodes were detected using special equipment. Criteria for inclusion of patients in the clinical trial: 1) breast cancer patients of any age with T1-3N0M0, I-II AB disease stage; 2) patients with clinically unaffected lymph nodes N0 after examination. Criteria for exclusion of patients from the clinical trial: The exceptions were T3-T4 tumors > 5 cm in diameter, or the skin and chest wall invasion, as well as palpable axillary lymph nodes, 3 or more affected lymph nodes with sentinel lymph node biopsy; 3) patients after radiation therapy. Results. The tumor histology was performed after the node trephine biopsy. The main aims of sentinel nodes detection were staging and improving the breast cancer patients’ life quality after surgical treatment. The post-mastectomy syndrome, the main manifestation of which is swelling of the upper extremity is a big problem for patients because it affects their life quality and disturbs their usual lifestyle. The sentinel lymph node detection, in contrast to axillary lymph node dissection of I-II level, significantly minimizes all the risks of postmastectomy syndrome, in particular, impaired lymphatic drainage in the form of lymphatic edema of the upper extremity, impaired venous outflow in the form of stenoses or the axillary and/or subclavian veins occlusion, rough scars which limit the function of the extremity in the shoulder joint, and brachioplexitis. Conclusions. The study of sentinel lymph nodes significantly improves the results of surgical treatment of breast cancer patients. Based on the clinical-laboratory and histological examinations, new data were obtained concerning the sentinel lymph node detection using two dyes, the choice of the surgical intervention volume and reduction of complications rate at the postoperative period. We found that fluorescent lymphography is highly effective, which allows to recommend it for implementation into the clinical practice. The frequency of sentinel lymph node detection in breast cancer patients is 98% in the control group, 100% – in the main group. On the basis of the obtained results, the sentinel lymph node detection algorithm and the surgical management of patients with breast cancer was developed and implemented into practice, which allowed to reduce the number of complications with using two dyes for the sentinel lymph node detection from 19% to 2% (χ2 =15.37, p<0.001). Recurrence of breast cancer fell from 13% to 8%.
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, S., J. Yang, S. Nam, J. Lee, W. Kim, J. Choi, G. Kim, and G. Kim. "Triple detection method for sentinel lymph node detection." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e11605-e11605. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e11605.

Full text
Abstract:
e11605 Background: Sentinel lymph node biopsy is widely accepted method to determine nodal stage of breast cancer. There are several reported method for detecting sentinel lymph node. The aim of this study was to show the new detection method of sentinel lymph node and show the effectiveness of this method. Methods: We did prospective study and enrolled 25 patients who underwent partial mastectomy and sentinel lymph node biopsy. We injected indigocyanine green (green dye) at peritumoral lesion, indigocarmine dye (blue dye) in subareolar area and radioisotope (Tc-99m) injection. Sentinel lymph nodes are identified by color change or radioisotope uptake, and classified by each color (blue or green) and radioisotope uptake. We compared the detection rate from our study with that from the previous studies. Results: Sentinel lymph nodes were detected in all patients (25/25). Green color stained sentinel lymph nodes were identified in 18 patients (18/25), blue color stained sentinel lymph nodes were identified in 15 patients (15/25) and radioactive lymph nodes were identified in 19 patients (19/25). Conclusions: The triple mapping method showed higher detection rate than the previous studies and this method is recommendable to detect sentinel lymph node. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
3

Coibion, Michel, Fabrice Olivier, Audrey Courtois, Nathalie Maes, Véronique Jossa, and Guy Jerusalem. "A Randomized Prospective Non-Inferiority Trial of Sentinel Lymph Node Biopsy in Early Breast Cancer: Blue Dye Compared with Indocyanine Green Fluorescence Tracer." Cancers 14, no. 4 (February 10, 2022): 888. http://dx.doi.org/10.3390/cancers14040888.

Full text
Abstract:
Background: Indocyanine green (ICG) is a promising tracer for sentinel lymph node biopsy in early breast cancer. This randomized study was conducted to evaluate sentinel lymph node biopsy with ICG compared with blue dye as a tracer in woman with early breast cancer without any sign of lymph node invasion. Methods: Between January 2019 and November 2020, 240 consecutive women with early breast cancer were enrolled and randomized to sentinel lymph node biopsy using ICG or blue dye. The primary endpoint was the sentinel lymph node detection rate in both arms. Results: ICG was used in 121 patients and detected sentinel lymph nodes in all patients (detection rate, 100%; 95% CI: 96.9–100.0) while blue dye was used in 119 patients and detected sentinel lymph nodes in 116 patients (detection rate: 97.5%, 95% CI: 92.9–99.1). This analysis indicated the non-inferiority of ICG vs. blue dye tracer (90%CI: −1.9–6.9; p = 0.0009). Conclusion: ICG represents a new promising tracer to detect sentinel lymph nodes in early breast cancer with a detection rate similar to other conventional tracers, and is associated with easy learning and low cost. Our result suggest that this technique is a good alternative to avoid radioactive isotope manipulation.
APA, Harvard, Vancouver, ISO, and other styles
4

Portnoy, Sergey, A. Kuznetsov, N. Shakirova, Nikolay Kozlov, A. Maslyaev, A. Karpov, Yelena Kampova-polevaya, et al. "SENTINEL LYMPH NODE BIOPSY USING FLUORESCENT LYMPHOGRAPHY IN CT1-4N0M0 BREAST CANCER PATIENTS: HIGH DIAGNOSTIC CAPABILITIES." Problems in oncology 65, no. 2 (February 1, 2019): 243–49. http://dx.doi.org/10.37469/0507-3758-2019-65-2-243-249.

Full text
Abstract:
Breast cancer cT1-4N0M0 patients usually require a sentinel lymph node biopsy. Sentinel lymph node biopsy with indocyanine green fluorescence detection is a modern technique with a high lymph node detection rate. However, the false-negative rate was not evaluated adequately. Our objective was to determine node detection rate and the false-negative rate. 99 patients with 100 cases of breast cancer cT1-4N0M0 were operated on. The axillary part of an operation consisted of indocyanine green fluorescence-guided SLN biopsy and an axillary lymphadenectomy of levels I-II or I-П-Ш. A signal lymph node was detected in 98 cases (98 %). In 28 (28.6%) cases out of 98, metastases in signal lymph nodes were found. Other than sentinel lymph node had metastatic lesion only in 35.7% in SLN N+ cases. False negative result occurred in 1 case of 28 (3.6%). The application of indocyanine green fluorescence-guided sentinel lymph node biopsy in cN0 breast cancer patients allows for a high signal lymph node detection rate and a low false negative rate.
APA, Harvard, Vancouver, ISO, and other styles
5

Song, B., J. Bae, J. Kim, H. Jeon, and S. Jung. "Comparing study of positron emission tomography and ultrasonography in the detection of axillary lymph node metastasis in patients with early stage breast cancer." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 616. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.616.

Full text
Abstract:
616 Background: The current status of axillary lymph node is the most important prognostic factor in breast cancer. Axillary lymph node dissection (ALND) is currently the standard option for assessment of axillary lymph nodes. Positron emission tomography - computerized tomography (PET-CT) imaging and breast sonography are a noninvasive imaging modality that can detect malignant lymph node. The purpose of this study was to evaluate the clinical usefulness of axillary lymph node staging by means of PET-CT imaging compare with breast sonography in breast cancer. Methods: This study involves 129 breast cancer patients and clinically negative axillary node. All patients had whole body PET-CT imaging and breast sonography before SLN biopsy. After SLN biopsy, all patients underwent complete ALND. Axillary lymph nodes were evaluated by standard hematoxylin and eosin staining techniques, while sentinel nodes were further examined for micrometastatic disease. The findings of PET-CT imaging and breast sonography of 129 patients were compared with pathologic findings after operation. Diagnostic accuracy was evaluated applying ROC curve areas. Results: The sensitivity of PET-CT imaging was 60.0%; specificity and accuracy were 83.6% and 73.4%, respectively. The sensitivity, specificity and accuracy of breast sonography were 61.8%, 89.0%, and 77.3% respectively. The SUVs of axillary lymph node ranged from 0.0 to 7.01. Analysis using ROC curves revealed the area under each curve which indicated a diagnostic accuracy. For involvement of axillary lymph node, PET-CT imaging had the area under the curve of 0.735, breast sonography one of 0.769. Conclusions: Axillary lymph node staging using PET-CT imaging is inferior to the breast sonography in early stage of breast cancer patients. Our study reveals the value of PET-CT imaging is not good compare to the breast sonography in the detection of axillary lymph nodes metastasis in patients with early breast cancer. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
6

Mátrai, Zoltán, László Tóth, Toshiaki Saeki, István Sinkovics, Mária Gődény, Hideki Takeuchi, Mária Bidlek, et al. "The potential role of SPECT/CT in the preoperative detection of sentinel lymph nodes in breast cancer." Orvosi Hetilap 152, no. 17 (April 2011): 678–88. http://dx.doi.org/10.1556/oh.2011.29077.

Full text
Abstract:
Regional lymph node status is the most important prognostic factor in breast cancer. Sentinel lymph node biopsy is the standard method of axillary staging in early breast cancer patients with clinically negative nodes. Preoperative lymphoscintigraphy might support refining biopsy findings by determining the number and location of sentinel lymph nodes. In aged or overweight patients, in the presence of atypical or extra-axillary lymphatic drainage, non-visualized lymph nodes, or sentinel lymph nodes close to the isotope injection site, detection could be aided by a new, hybrid imaging tool: the single-photon emission computed tomography combined with computed tomography (3D SPECT/CT). For the first time in Hungarian language, authors overview the literature: all 14 English-language articles on the implementation of 3D SPECT/CT in sentinel lymph node detection in breast cancer are included. It is concluded that 3D SPECT/CT increases the success rate and quality of preoperative sentinel node identification, and is capable of providing a more accurate staging of breast cancer patients in routine clinical practice. Orv. Hetil., 2011, 152, 678–688.
APA, Harvard, Vancouver, ISO, and other styles
7

Huang, Yihong, Shuo Zheng, and Baoyong Lai. "Analysis of the Mechanism of Breast Metastasis Based on Image Recognition and Ultrasound Diagnosis." Journal of Healthcare Engineering 2021 (October 11, 2021): 1–11. http://dx.doi.org/10.1155/2021/4452500.

Full text
Abstract:
Breast cancer is one of the cancers with the highest incidence among women. In the late stage, cancer cells may metastasize to a distance, causing multiple organ diseases, threatening the lives of patients. The detection of lymph node metastasis based on pathological images is a key indicator for the diagnosis and staging of breast cancer, and correct staging decisions are the prerequisite and basis for targeted treatment. At present, the detection of lymph node metastasis mainly relies on manual screening by pathologists, which is time-consuming and labor-intensive, and the diagnosis results are variable and subjective. The automatic staging method based on the panoramic image calculation of the sentinel lymph node of the breast proposed in this paper can provide a set of standardized, high-accuracy, and repeatable objective diagnosis results. However, it is very difficult to automatically detect and locate cancer metastasis areas in highly complex panoramic images of lymph nodes. This paper proposes a novel deep network training strategy based on the sliding window to train an automatic localization model of cancer metastasis area. The training strategy first trains the initial convolutional network in a small amount of data, extracts false-positive and false-negative image blocks, and uses manual screening combined with automatic network screening to reclassify the false-positive blocks to improve the class of negative categories. Using mammography, ultrasound, MRI, and 18F-FDG PET-CT examinations, the detection rate and diagnostic accuracy of primary cancers in the breast of patients with axillary lymph node metastasis as the first diagnosis were obtained. The detection rate and diagnostic accuracy of breast MRI for primary cancers in the breast are much higher than those of X-ray, ultrasound, and 18F-FDG PET-CT (all P values <0.001). Mammography, ultrasound, and PET-CT examinations showed no difference in the detection rate and diagnostic accuracy of primary cancers in the breast of patients with axillary lymph node metastasis as the first diagnosis. Breast MRI should be used as a routine examination for patients with axillary lymph node metastasis as the first diagnosis. The primary breast cancer in the first diagnosed patients with axillary lymph node metastasis is often presented as localized asymmetric compactness or calcification on X-ray; it often appears as small focal mass lesions and ductal lesions without three-dimensional space-occupying effect on ultrasound.
APA, Harvard, Vancouver, ISO, and other styles
8

Liu, Pengcheng, Jie Tan, Yuting Song, Kai Huang, Qingyi Zhang, and Huiqi Xie. "The Application of Magnetic Nanoparticles for Sentinel Lymph Node Detection in Clinically Node-Negative Breast Cancer Patients: A Systemic Review and Meta-Analysis." Cancers 14, no. 20 (October 14, 2022): 5034. http://dx.doi.org/10.3390/cancers14205034.

Full text
Abstract:
Superparamagnetic iron oxide (SPIO), an alternative mapping agent, can be used to identify sentinel lymph nodes in patients with clinically node-negative breast cancer. However, its performance in comparison with the standard method, using a radioisotope (technetium-99 m, Tc) alone or in combination with blue dye, remains controversial. Hence, a systematic review and meta-analysis were conducted to evaluate the diagnostic accuracy of SPIO and its clinical impact in the management of breast cancer. The PubMed, Embase, and Cochrane databases were comprehensively searched from inception to 1 May 2022. Cohort studies regarding the comparison of SPIO with standard methods for sentinel lymph node identification were included. A total of 19 prospective cohort studies, which collectively included 2298 clinically node-negative breast cancer patients undergoing sentinel lymph node identification through both the standard method and SPIO, were identified. The detection rate for sentinel lymph nodes (RR, 1.06; 95% CI, 1.05–1.08; p < 0.001) was considerably higher in the SPIO cohorts than in the standard method cohorts, although this difference was not significant in detected patients, patients with positive sentinel lymph nodes, or positive sentinel lymph nodes. Compared with the standard method, the SPIO method could be considered as an alternative standard of care for sentinel lymph node detection in patients with clinically node-negative breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
9

Euscher, Elizabeth. "Pathology of sentinel lymph nodes: historical perspective and current applications in gynecologic cancer." International Journal of Gynecologic Cancer 30, no. 3 (February 19, 2020): 394–401. http://dx.doi.org/10.1136/ijgc-2019-001022.

Full text
Abstract:
Efforts to reduce surgical morbidity related to en bloc lymph node removal associated with cancer surgery led to the development of targeted lymph node sampling to identify the lymph node(s) most likely to harbor a metastasis. Through identification of one or only a few lymph nodes at highest risk, the overall number of lymph nodes removed could be markedly reduced. Submission of fewer lymph nodes affords more detailed pathologic examination than would otherwise be practical with a standard lymph node dissection. Such enhanced pathologic examination techniques (ie, ultra-staging) have contributed to increased detection of lymph node metastases, primarily by detection of low volume metastatic disease. Based on the success of sentinel lymph node mapping and ultra-staging in breast cancer and melanoma, such techniques are increasingly used for other organ systems including the gynecologic tract. This review addresses the historical aspects of sentinel lymph node evaluation and reviews current ultra-staging protocols as well as the implications associated with increased detection of low volume metastases.
APA, Harvard, Vancouver, ISO, and other styles
10

Pelosi, E., V. Arena, B. Baudino, M. Bellò, R. Giani, D. Lauro, A. Ala, R. Bussone, and G. Bisi. "Sentinel Node Detection in Breast Carcinoma." Tumori Journal 88, no. 3 (May 2002): S10—S11. http://dx.doi.org/10.1177/030089160208800323.

Full text
Abstract:
Aims and Background The standard procedure for the evaluation of axillary nodal involvement in patients with breast cancer is still complete lymph node dissection. However, about 70% of patients are found to be free of metastatic disease while axillary node dissection may cause significant morbidity. Lymphatic mapping and sentinel lymph node (SLN) biopsy are changing this situation. Methods and Study Design In a period of 18 months we studied 201 patients with breast cancer, excluding patients with palpable axillary nodes, tumors >2.5 cm in diameter, multifocal or multicentric cancer, pregnant patients and patients over 80 years of age. Before surgery 99mTc-labeled colloid and vital blue dye were injected into the breast to identify the SLN. In lymph nodes dissected during surgery the metastatic status was examined by sections at reduced intervals. Only patients with SLNs that were histologically positive for metastases underwent axillary dissection. Results We localized one or more SLNs in 194 of 201 (96.5%) patients; when both techniques were utilized the success rate was 100%. Histologically, 21% of patients showed SLN metastases (7.8% micrometastases) and 68% of these had metastases also in other axillary nodes. None of the patients with negative SLNs developed metastases during follow-up. Conclusions At present there is no definite evidence that negative SLN biopsy is invariably correlated with negative axillary status; however, our study and those of others demonstrate that SLN biopsy is an accurate method of axillary staging.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Lymph node;breast cancer;detection"

1

Chen, Wan Qing. "Predictors of Auxillary Lymph Node Involvement in Screen Detected Breast Cancer." Thesis, The University of Sydney, 2004. http://hdl.handle.net/2123/676.

Full text
Abstract:
Background: Axillary lymph node dissection as routine part of breast cancer treatment has been questioned in relation to the balance between benefits and morbidity. The purpose of this study is to determine the association of tumor size, age and histological grade with axillary lymph node metastasis, to determine if some patients could be exempted from axillary dissection. Methods: The data are derived from BreastScreen NSW, the government sponsored population-based breast screening program. In New South Wales (NSW) Australia between 1995 and 2002, 7,221 patients with invasive breast carcinoma were diagnosed and 5,290 patients were eligible for this study. The relationship between incidence of positive axillary lymph nodes and three study factors (tumor size, age and histological grade) was investigated by univariate and multivariate analysis. Logistic regression models were used to predict probability of axillary metastases. Results: The incidence of axillary lymph node metastases was 28.6% (95% CI: 27.4%- 29.8%). Univariate analysis showed that age, tumor size and histological grade were significant predictors of axillary lymph node metastases (p<0.0001). Multivariate analysis identified age, tumor size and histological grade remained as independent predictors (p<0.0001). From multivariate analysis, patients with T1a (Less than or equal to 5mm) and grade I tumors regardless of age had 5.2% (95% CI: 1.2%- 9.3%) frequency of node metastases. Patients 70 years or older with grade I, T1a and T1b (6-10mm) tumors had 4.9% (95% CI: 3.2%- 7.5%) and 6.6% (95% CI: 5.3%-8.3%) predicted frequency of node metastases. Conclusions: Tumor size, age and histological grade are predictors of axillary lymph node metastases. Routine axillary lymph node dissection could be avoided in some patient groups with a low frequency of involved lymph nodes if the benefits are considered to exceed the risks.
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Wan Qing. "Predictors of Auxillary Lymph Node Involvement in Screen Detected Breast Cancer." University of Sydney. Public Health, 2004. http://hdl.handle.net/2123/676.

Full text
Abstract:
Background: Axillary lymph node dissection as routine part of breast cancer treatment has been questioned in relation to the balance between benefits and morbidity. The purpose of this study is to determine the association of tumor size, age and histological grade with axillary lymph node metastasis, to determine if some patients could be exempted from axillary dissection. Methods: The data are derived from BreastScreen NSW, the government sponsored population-based breast screening program. In New South Wales (NSW) Australia between 1995 and 2002, 7,221 patients with invasive breast carcinoma were diagnosed and 5,290 patients were eligible for this study. The relationship between incidence of positive axillary lymph nodes and three study factors (tumor size, age and histological grade) was investigated by univariate and multivariate analysis. Logistic regression models were used to predict probability of axillary metastases. Results: The incidence of axillary lymph node metastases was 28.6% (95% CI: 27.4%- 29.8%). Univariate analysis showed that age, tumor size and histological grade were significant predictors of axillary lymph node metastases (p<0.0001). Multivariate analysis identified age, tumor size and histological grade remained as independent predictors (p<0.0001). From multivariate analysis, patients with T1a (Less than or equal to 5mm) and grade I tumors regardless of age had 5.2% (95% CI: 1.2%- 9.3%) frequency of node metastases. Patients 70 years or older with grade I, T1a and T1b (6-10mm) tumors had 4.9% (95% CI: 3.2%- 7.5%) and 6.6% (95% CI: 5.3%-8.3%) predicted frequency of node metastases. Conclusions: Tumor size, age and histological grade are predictors of axillary lymph node metastases. Routine axillary lymph node dissection could be avoided in some patient groups with a low frequency of involved lymph nodes if the benefits are considered to exceed the risks.
APA, Harvard, Vancouver, ISO, and other styles
3

Doting, Meintje Hylkje Edwina. "Sentinel lymph node biopsy in breast cancer and melanoma." [S.l. : [Groningen : s.n.] ; University Library Groningen] [Host], 2007. http://irs.ub.rug.nl/ppn/300326254.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chen, Wanqing. "Predictors of axillary lymph node involvement in screen-detected breast cancer." Connect to full text, 2004. http://setis.library.usyd.edu.au/adt/public_html/adt-NU/public/adt-NU20050104.165451/index.html.

Full text
Abstract:
Thesis (M.I.P.H.)--School of Public Health, University of Sydney, 2004.
"This treatise is submitted in partial satisfaction of the requirements for the Degree of Master of International Public Health (Hons), University of Sydney". Bibliography: leaves 10-15.
APA, Harvard, Vancouver, ISO, and other styles
5

Ahlgren, Johan. "Studies on Prediction of Axillary Lymph Node Status in Invasive Breast Cancer." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2002. http://publications.uu.se/theses/91-554-5221-3/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Johnson, Laura. "Magnetic nanoparticles for sentinel lymph node imaging and biopsy in breast cancer." Thesis, King's College London (University of London), 2012. https://kclpure.kcl.ac.uk/portal/en/theses/magnetic-nanoparticles-for-sentinel-lymph-node-imaging-and-biopsy-in-breast-cancer(978692de-a495-4df1-ac0f-303227bed0dd).html.

Full text
Abstract:
Background Axillary nodal status is the single most important prognostic factor in breast cancer diagnosis. If cancerous cells are present, the sentinel lymph node (SLN) is the axillary lymph node that is most likely to contain metastatic disease. In early stage breast cancer, the SLN is localised (then surgically removed for pathological analysis) using a radioisotope and/or a blue dye injected into the breast Super-paramagnetic iron oxide (SPIO) nanoparticles are novel agents that, when injected, could potentially both localise and characterise the SLN using MRI such that surgical SLN biopsy is no longer required. Aims To evaluate axillary SLN localisation after SPIO injection with, pre-operatively, axillary MRI and, intra-operatively, with a hand held magnetometer and to characterise SLN SPIO uptake using ex-vivo MRI. Methods From November 2009 - March 2011, 51 patients with early stage breast cancer underwent SLN biopsy following a subcutaneous injection of SPIO in addition to the standard injection of radioisotope (Tc99M) and blue dye. SPIO injection technique was refined during the trial with an initial dose of 2mls and then 4mls in 8 and then 43 women respectively. Pre-operative axillary in vivo MRI (1.5T) was carried out on 14 women and ex vivo high resolution MRI (9.4T) on 36 nodes. During surgery, an SLN was defined as either "hot", "blue", "palpable" or "SPIO detected". Axillary clearance was carried out for SLN-positive disease. Results In total, 11 of the 51 patients had positive SLNs. On pre-operative axillary MRI, SPIO uptake was noted in at least one node in all 14 patients. A total of 35 nodes were identified. Uptake of SPIO in the SLN was seen at a minimum of 12mins post injection. Involved SLNs were not differentiated from normal SLNs following morphological characterisation or based on loss of T2 signal within the individual SLN. At SLN biopsy, 134 hot, blue, palpable or SPIO-containing nodes were identified in 51 patients. The magnometer identified 92 SPIO-containing nodes in 51 (84%) patients. One node in one patient was not identified using the combined technique but was found to contain SPIO. Of the 16 hot, blue or palpable involved nodes in 11 patients, 9 contained SPIO. In summary, the SPIO SLN localisation rate and FNR in patients was 84% and 16% respectively. Ex vivo SLN MRI demonstrated SPIO uptake in all 35 SLNs preferential to the sinuses and sub-capsular spaces. Of the 3 involved nodes, areas of metastasis did not take up SPIO, whereas in normal areas of the node, SPIO was positively identified. Conclusion In our study, subcutaneous SPIO, a novel SLN-localising agent, was taken up by axillary nodes and identified on pre-operative axillary MRI. Node positive SLNs were identified on ex vivo MRI, but SPIO did not demonstrate sufficient accuracy at SLN localisation for routine clinical use.
APA, Harvard, Vancouver, ISO, and other styles
7

Bhattarai, Nihit. "Differentiation Mechanisms of Myeloid-Lymphatic Progenitors that Promote Lymph Node Metastasis in Breast Cancer." OpenSIUC, 2020. https://opensiuc.lib.siu.edu/theses/2657.

Full text
Abstract:
Metastasis to distant organs, a major cause of mortality from cancer, is often preceded by tumor spread to regional lymph nodes (LN). This process is supported exclusively by lymphatic vessels within or around the tumor. It is important to understand the mechanism by which tumors induce generation of new lymphatic vessels because interference with this early stage of tumor spread might prevent distant metastasis. Tumor lymphatic formation is thought to be induced by VEGF-C factor that activates its receptor VEGFR-3 expressed in lymphatic endothelial cells (LEC). However, this process also requires participation of tumor-recruited Myeloid-Lymphatic Endothelial Cell Progenitors (M-LECPs). We recently showed that M-LECPs are abundant in mouse and human breast tumors and that their density strongly correlates with both lymphatic formation and nodal metastasis. Here, we show that M-LECPs derived from bone marrow (BM) myeloid precursors can be differentiated in vitro by pretreatment with colony stimulating factor-1 (CSF-1) followed by activation of Toll-like Receptor-4 (TLR4) applied in this but not in a reverse order. We also identified CSF-1 as the best inducer of M-LECP differentiation out of 16 screened cytokines. Based on flow cytometry analysis of LEC- and myeloid-specific markers, CSF-1R-positive cells yielded significantly higher number of myeloid-lymphatic endothelial progenitors than BM cells lacking this receptor. Consistently, both anti-CSF-1R antibody and BLZ945 drug significantly reduced the number of myeloid-lymphatic progenitors compared with untreated controls. We also found that the requirement for CSF-1 to precede activation of TLR4 pathway is likely routed in CSF-1 dependent upregulation of essential components of TLR4 ligand recognition complex such as MD2, CD14, CD11b and CD18. In conclusion, we show that mouse BM cells can be differentiated into lymphatic endothelial progenitors by treatment with CSF-1 and TLR4 ligand, LPS. We also show that treatment with CSF-1 has to precede activation of TLR4 pathway as upregulation of several components of the TLR4 pathway is required for optimal M-LECP differentiation. To our knowledge, this is the first evidence identifying specific factors and sequence of their exposure that drive the formation of the lymphatic endothelial lineage from early myeloid precursors.
APA, Harvard, Vancouver, ISO, and other styles
8

Owusu, Miriam Sekyere. "Lymphedema, post breast cancer treatment at Komfo Anokye Teaching Hospital, Kumasi, Ghana." Thesis, Cape Peninsula University of Technology, 2011. http://hdl.handle.net/20.500.11838/2262.

Full text
Abstract:
Thesis (MTech (Nursing))--Cape Peninsula University of Technology, 2011.
To determine the incidence, risk factors and the treatment of lymphedema after breast cancer treatment at the oncology unit of KATH, Kumasi, Ghana from 01 January 2005 to 31 December 2008. Descriptive retrospective survey was used. Using a data capture sheet, data was collected from the medical records of the breast cancer patients. Breast cancer and lymphedema-related variables were collected. Data was analyzed as descriptive statistics. Chi-square test was applied to determine whether or not two variables are independent variables. Among 313 patients treated for breast cancer between 2005 and 2008, 31 (9.9%) developed lymphedema after treatment. A chi-square test showed that axillary lymph node dissection was statistically a significant risk factor of lymphedema (Chi-square test value=7.055, P value=0.008). Radiation and late stage of breast cancer diagnosis may have contributed in development of lymphedema despite having P value> 0.05. Age, body mass index (BMI) and hypertension were also not associated with lymphedema.
APA, Harvard, Vancouver, ISO, and other styles
9

de, Boniface Jana. "Sentinel Node Biopsy in Breast Cancer : Clinical and Immunological Aspects." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7890.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vasques, Paulo Henrique DiÃgenes. "Comparison between hemosiderin and technetium-99 in the identification of sentinel lymph node in breast cancer." Universidade Federal do CearÃ, 2016. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=16007.

Full text
Abstract:
CoordenaÃÃo de AperfeÃoamento de Pessoal de NÃvel Superior
Introduction and objective: Sentinel Lymph Node Biopsy (SLNB) has currently replaced axillary dissection in early-stage breast cancer in clinically tumor-free patients. Technetium-99 (99Tc) is the gold standard for the identification of Breast Sentinel Lymph Node (SLN). Blue dyes are a less expensive and widely used option in Brazil. These dyes are responsible for several adverse and hypersensitivity reactions that â although rare â can put patientsâ lives at risk. There is an interest in the discovery of new equivalent substances with less side effects than those used in SLNB. This research assesses the safety and equivalence of the use of hemosiderin in SLNB in breast cancer compared to technetium-99 (99Tc). Hemosiderin is a hemoglobin derivate identified in a preclinical trial that has proven to be effective in the SLNB of female dogsâ breasts. The aim of this research is to assess the safety and potential equivalence of the use of hemosiderin in SLNB in human breast compared to the 99Tc. Method: The experiments took place in the period from September 2011 to September 2013. Patients were selected from the Mastology Service of the MEAC/HC/UFC and included 14 volunteer women with breast cancer with primary tumors (T1/T2) and clinically tumor-free axilla who were submitted to SLNB using hemosiderin, produced based on an aseptic hemolysate obtained from autologous blood, injected in the periareolar region 24h before surgery on an outpatient basis. 0.5 mCi of 99Tc was also injected in the subareolar region in the immediate preoperative period. Patients underwent breast MRI and mammary scintigraphy. In the operating room, patients â under general anesthesia â were submitted to SLNB, with incision in the axillary fold guided by Gamma-Probe and dissection by planes until the identification of the point of maximum uptake of 99Tc, identifying the marked sentinel lymph nodes (SLN) and their colors. Breast procedure was defined based on the correlation of the size and location of primary tumor and the axilla procedure was performed based on the presence or not of SLN metastasis. All surgical specimens were sent for pathological and immunohistochemical study. Results: There were no side effects, allergic reactions, surgical infection or toxicity related to the method applied. The conocordance rate between hemosiderin and 99Tc was 100%. The sensitivity and accuracy of hemosiderin was 100%. An incidental finding refers to magnetic properties of axillary lymph nodes (ALN) identified as an hypersignal in the NMR with hemosiderin in 100% of the exams. In two of four cases with positive SLN on histopathology, the image of the NMR with hemosiderin suggested neoplastic involvement of the marked lymph node. Conclusion: Hemosiderin proved to be an efficient and safe dye that is equivalent to 99Tc in breast SLNB.
IntroduÃÃo e objetivo: Atualmente, a Biopsia do Linfonodo Sentinela (BLS) substitui o esvaziamento axilar no estadiamento do cÃncer de mama inicial com axila clinicamente negativa. O tecnÃcio 99 (Tc99) à o padrÃo ouro para identificaÃÃo do Linfonodo Sentinela (LS) da mama. Os corantes azuis sÃo uma opÃÃo menos onerosa e mais difundida no Brasil. Estes corantes sÃo responsÃveis pelas reaÃÃes adversas e de hipersensibilidade que, embora raras, podem pÃr em risco à vida dos pacientes. Hà interesse na descoberta de novas substÃncias equivalentes e com menores efeitos colaterais Ãs usadas na BLS. Aqui se avaliam a seguranÃa e a equivalÃncia do uso da hemossiderina, em comparaÃÃo ao tecnÃcio 99 (Tc99) na BLS no cÃncer de mama. A hemossiderina à um derivado da hemoglobina, identificada em estudo prÃ-clÃnico, que se mostrou eficaz na BLS da mama da cadela. O objetivo desta pesquisa à avaliar a seguranÃa e a potencial equivalÃncia do uso da hemossiderina em comparaÃÃo com o Tc99 na BLS da mama humana. MÃtodo: Os experimentos ocorreram no perÃodo de setembro de 2011 a setembro de 2013. As pacientes selecionadas no ServiÃo de Mastologia da MEAC/HC/UFC, foram 14 mulheres, voluntÃrias, portadoras de cÃncer de mama, com tumores iniciais (T1/T2) e axila clinicamente negativa, que se submeteram a BLS, utilizando hemossiderina, produzida com base em um hemolisado, assÃptico, obtido de sangue autÃlogo, injetada na regiÃo subareolar, ambulatorialmente, 24h antes da cirurgia. No prÃ-operatorio imediato, injetou-se, tambÃm, na regiÃo subareolar, 0,5mci de Tc99. As pacientes foram submetidas a ressonÃncia magnÃtica das mamas, e a cintilografia mamÃria. No Centro CirÃrgico, as pacientes sob anestesia geral realizaram a BLS com incisÃo na prega axilar, guiada pelo gamma-probe, dissecÃÃo por planos atà a identificaÃÃo de ponto de captaÃÃo mÃxima do Tc99, identificando-se o Linfonodo Sentinela (LS) marcado e a sua coloraÃÃo. O procedimento da mama foi definido em correlaÃÃo com o tamanho e localizaÃÃo do tumor primÃrio e a conduta em relaÃÃo à axila em funÃÃo da presenÃa ou ausÃncia de metÃstase no LS. Toda peÃa cirÃrgica foi encaminhada à avaliaÃÃo anatomopatolÃgica e imunohistoquÃmica. Resultados: NÃo foram observados efeitos colaterais, reaÃÃes alÃrgicas, infecÃÃo cirÃrgica ou toxicidade relacionados ao mÃtodo empregado. A taxa de concordÃncia entre a hemosiderina e o Tc99 foi de 100%. A sensibilidade e acurÃcia da hemossiderina foi 100%. Um achado incidental foi o magnetismo dos linfonodos axilares (LA) identificados como hipersinal à RNM com hemossiderina em 100% dos exames. Em dois de quatro casos de LS positivos na histopatologia, a imagem da RNM com hemossiderina sugeria comprometimento neoplÃsico do linfonodo marcado. ConclusÃo: A hemossiderina se mostrou um corante eficiente, seguro e equivalente ao TecnÃcio 99 na BLS da mama
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Lymph node;breast cancer;detection"

1

Leong, Stanley P. L. Atlas of Selective Sentinel Lymphadenectomy for Melanoma, Breast Cancer and Colon Cancer. Cleveland: Kluwer Academic Publishers, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Branagan, Graham. Comparison between histological and molecular biological methods of detecting breast cancer metastases in sentinel and non-sentinel lymph nodes. Portsmouth: University of Portsmouth, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Charles, Levenback, Zee, Ate G. J. van der., and Coleman Robert, eds. Clinical lymphatic mapping in gynecologic cancers. London: Taylor & Francis, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Oxley, Jill Suzanne. The prospective role of duplex ultrasound and magnetic resonance imaging in the evaluation of axillary lymph node involvement in breast cancer. [New Haven, Conn: s.n.], 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

House, United States Congress. A bill to require that health plans provide coverage for a minimum hospital stay for mastectomies and lymph node dissection for the treatment of breast cancer, and coverage for secondary consultations. Washington, D.C: U.S. G.P.O., 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

United States. Congress. House. A bill to require that health plans provide coverage for a minimum hospital stay for mastectomies, lumpectomies, and lymph node dissection for the treatment of breast cancer and coverage for secondary consultations. [Washington, D.C.?]: [United States Government Printing Office], 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

United States. Congress. Senate. A bill to amend the Public Health Service Act and Employee Retirement Income Security Act of 1974 to require that group and individual health insurance coverage and group health plans provide coverage for a minimum hospital stay for mastectomies and lymph node dissections performed for the treatment of breast cancer. Washington, D.C: U.S. G.P.O., 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1948-, Dana Suzanna E., ed. Handbook of forensic pathology. 2nd ed. Boca Raton: CRC/Taylor & Francis, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1948-, Dana Suzanna E., ed. Handbook of forensic pathology. Austin, Tex: Landes Bioscience, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Reiser, Maximilian F., Alfred Schauer, Kurt Possinger, and Wolfgang Becker. Sentinel Lymph Node Concept. Springer London, Limited, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Lymph node;breast cancer;detection"

1

Finas, Dominique, Kristin Baumann, Katja Heinrich, Britta Ruhland, Lotta Sydow, Ksenija Gräfe, Timo Sattel, Kerstin Lüdtke-Buzug, and Thorsten Buzug. "Distribution of Superparamagnetic Nanoparticles in Lymphatic Tissue for Sentinel Lymph Node Detection in Breast Cancer by Magnetic Particle Imaging." In Springer Proceedings in Physics, 187–91. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-24133-8_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Turki, Turki, Anmar Al-Sharif, and Y.-h. Taguchi. "End-to-End Deep Learning for Detecting Metastatic Breast Cancer in Axillary Lymph Node from Digital Pathology Images." In Intelligent Data Engineering and Automated Learning – IDEAL 2021, 343–53. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-91608-4_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Blidaru, Alexandru, Cristian Ioan Bordea, Mihaela Radu, Aniela Noditi, and Ioana Iordache. "Sentinel Lymph Node Biopsy Techniques." In Breast Cancer Essentials, 487–98. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73147-2_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Steyerova, Petra, and David Kachlik. "Breast and Lymph Node Anatomy." In Breast Cancer Radiation Therapy, 69–79. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-91170-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Charalampoudis, Petros, and Christos Markopoulos. "Current Concept of Sentinel Lymph Node Biopsy." In Breast Cancer Essentials, 499–507. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73147-2_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Goyal, Amit, and Robert E. Mansel. "Sentinel lymph node biopsy in early-stage breast cancer." In Metastasis of Breast Cancer, 333–53. Dordrecht: Springer Netherlands, 2007. http://dx.doi.org/10.1007/978-1-4020-5867-7_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ho, Alice Y., Samantha A. Dunn, and Simon Powell. "Regional Lymph Node Irradiation for Breast Cancer." In Practical Guides in Radiation Oncology, 137–45. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-99590-4_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Siegel, Emily, John Kiluk, Armando Giuliano, and Brian Czerniecki. "Sentinel Lymph Node Biopsy in Breast Cancer." In Cancer Metastasis Through the Lymphovascular System, 353–60. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-93084-4_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Crown, Angelena, and Mary L. Gemignani. "Sentinel lymph node mapping in breast cancer." In Clinical Lymphatic Mapping in Gynecologic Cancers, 83–98. 2nd ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9781003255536-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bergkvist, Leif, and Jan Frisell. "Management of the Axilla: Sentinel Lymph Node Biopsy." In Breast Cancer Management for Surgeons, 275–84. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56673-3_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Lymph node;breast cancer;detection"

1

Jiang, Daohuai, Jiaxian Zhao, Yifan Zhang, Binbin Cong, Yuting Shen, Feng Gao, Yongsheng Wang, and Fei Gao. "Integrated Photoacoustic Pen for Breast Cancer Sentinel Lymph Node Detection." In 2022 IEEE International Ultrasonics Symposium (IUS). IEEE, 2022. http://dx.doi.org/10.1109/ius54386.2022.9958597.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Moreno, Andre, Kimberly Masiero Cola, Larissa Heberle, and Marcelo Moreno. "RELATIONSHIP BETWEEN IMMUNOHISTOCHEMICAL CHARACTERIZATION AND FORM OF DIAGNOSIS OF BREAST CANCER." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1008.

Full text
Abstract:
Introduction: Breast cancer is the most incident neoplasia among Brazilian women. According to immunogenetic characteristics, it is possible to verify that malignant breast neoplasms with greater biological activity would be those classified as luminary B, HER2+ and triple-negative, and that the one with the lowest biological activity would be the luminal subtype A. Thus, a mammography would be more likely to detect cancers with a low degree of biological characteristics such as “luminal A”. On the other hand, mammary carcinomas with greater potential for systemic dissemination show faster growth in the breast parenchyma and are detected predominantly by self-examination. Knowledge of this difference in the clinical behavior of mammary malignant neoplasms is important for the diagnosis of “interval” breast cancers, that is, breast cancer that appears in the period between the performance of annual screening mammograms. Objectives: Verify the relationship between immunohistochemical characterization of malignant breast neoplasms and the finding that motivated the medical consultation, in women with breast cancer and residents of Western Santa Catarina, Brazil. Methods: Observational, cross-sectional study, which included women diagnosed with breast cancer and treated at an oncology referral center in the city of Chapecó, state of Santa Catarina, Brazil, from January 2000 to December 2016. Patients that presented medical records whose main complaint was towards the diagnosis of breast cancer were included (example: nodule diagnosed by imaging exams, self-examination, clinical examination). Besides this, the breast injury related to this complaint should have been breast cancer diagnosed by an anatomopathological examination and an immunohistochemistry study. The project was developed in accordance to CEP/UNOCHAPECO no. 1819869. Results: Data from 209 patients were analyzed, from which 83 (39.7%) cases of breast cancer were detected by a mammography examination; 115 (55%) cases by breast self-examination and 11 (5.2%) cases by other forms of examination, which included clinical breast examination done by a doctor, magnetic resonance imaging and ultrasound. The luminal A immunohistochemical profile was more prevalent among patients who underwent breast cancer detection through mammography (62.6%). There was a correlation between lymph node invasion and the screening method, in which 78.6% of cancers detected by self-examination showed expansion to lymph nodes, while those detected by mammography presented an invasion rate of 45.7% (p=0.002). Conclusions: Breast cancer with immunohistochemical characterization, related to greater biological activity, were most often detected by self-examination, while neoplasms with indolent development were diagnosed predominantly by mammography.
APA, Harvard, Vancouver, ISO, and other styles
3

Johnson, L., QA Pankhurst, A. Purushotham, A. Brazdeikis, and M. Douek. "Abstract P1-01-23: Magnetic Sentinel Lymph Node Detection for Breast Cancer." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p1-01-23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wu, Yan, Yuxiang Lin, Yuane Lian, Peihua Lin, Shu Wang, Shuangmu Zhuo, Fangmeng Fu, Chuan Wang, and Jianxin Chen. "Detection of Axillary Lymph Node Metastasis in Breast Cancer using Mulitiphoton Microscopy." In International Conference on Photonics and Imaging in Biology and Medicine. Washington, D.C.: OSA, 2017. http://dx.doi.org/10.1364/pibm.2017.w3a.35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wang, Y., C. Wang, L. Fan, D. Mu, Y. Gao, J. Li, and W. Zhong. "Optimal detection of micrometastases in sentinel lymph node of breast cancer: CBCSG-001 trial." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-1011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Smeets, A., E. Yoshihara, A. Laenen, H. Wildiers, A. Reynders, J. Soens, R. Paridaens, et al. "P3-07-40: Impact of the Sentinel Lymph Node Procedure on the Detection of Positive Lymph Nodes in Breast Cancer." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p3-07-40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Conceicao, Raquel C., Luis Guilherme Oliveira, Brie Banks, and Elise Fear. "Development of axilla phantoms to aid breast cancer staging via sentinel lymph node detection." In 2014 8th European Conference on Antennas and Propagation (EuCAP). IEEE, 2014. http://dx.doi.org/10.1109/eucap.2014.6901808.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Papp, L., N. Zsoter, C. Loh, B. Ole, B. Egeler, I. Garai, and U. Luetzen. "Automated lymph node detection and classification on breast and prostate cancer SPECT-CT images." In 2011 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2011. http://dx.doi.org/10.1109/iembs.2011.6090928.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Maeno, K., K. Yamamoto, M. Ono, T. Oba, A. Iesato, K. Ono, T. Ito, T. Kanai, and K.-I. Ito. "Abstract P3-01-05: A feasibility study of sentinel lymph node detection and analysis of safety to omit axillary lymph node dissection in clinically node-negative breast cancer patients after neoadjuvant chemotherapy." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p3-01-05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

LeFrere Belda, M., A. Bats, C. Charon-Barra, H. Crouet, G. Houvenaeghel, K. Clough, A. Khaddage, et al. "Intra-operative sentinel lymph node metastasis detection by “one-step nucleic acid amplification (OSNA)”: results of the french multicentric study." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-1004.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Lymph node;breast cancer;detection"

1

Cavalli, Luciane R. Detection of Genetic Alterations in Breast Sentinel Lymph Node by Array-CGH. Fort Belvoir, VA: Defense Technical Information Center, October 2005. http://dx.doi.org/10.21236/ada444833.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cavalli, Luciane R. Detection of Genetic Alterations in Breast Sentinel Lymph Node by Array-CGH. Fort Belvoir, VA: Defense Technical Information Center, October 2006. http://dx.doi.org/10.21236/ada460808.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hassett, Mary. Outcomes by Ethnicity: Sentinel Lymph Node Status in Women with Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, April 2007. http://dx.doi.org/10.21236/ada495304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cheville, Andrea L. Assessment of Lymphedema Risk Following Lymph Node Dissection and Radiation Therapy for Primary Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2007. http://dx.doi.org/10.21236/ada485555.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cheville, Andrea L. Assesment of Lymphedema Risk Following Lymph Node Dissection and Radiation Therapy for Primary Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2008. http://dx.doi.org/10.21236/ada491730.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cheville, Andrea L. Assessment of Lymphedema Risk Following Lymph Node Dissection and Radiation Therapy for Primary Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2004. http://dx.doi.org/10.21236/ada433048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cheville, Andrea L. Assessment of Lymphedema Risk Following Lymph Node Dissection and Radiation Therapy for Primary Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, March 2011. http://dx.doi.org/10.21236/ada564266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cheville, Andrea L. Assessment of Lymphedema Risk Following Lymph Node Dissection and Radiation Therapy for Primary Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2005. http://dx.doi.org/10.21236/ada458225.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cheville, Andrea L. Assessment of Lymphedema Risk Following Lymph Node Dissection and Radiation Therapy for Primary Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2006. http://dx.doi.org/10.21236/ada462808.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wen, Zhenhua. Efficacy of sentinel lymph node biopsy versus standard axillary care for operable breast cancer: a systematic-review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Lymph node;breast cancer;detection' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography